Half-Year 2022 Financial and Clinical Trials Update

Lunsumio (mosunetuzumab, CD20 x CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Systemic lupus erythematosus (SLE) Phase/study # of patients ARM A: Lunsumio SC on either Day 1 or on Days 1 and 8 ARM B: Fractionated (divided) dose of Lunsumio SC on Days 1 and 8 Design - Safety Primary endpoint Status CT Identifier SC=subcutaneous FPI January 2022 Phase I N=50 NCT05155345 118 Roche Immunology

View entire presentation